Sugi Predict

Sugi Predict / Targets / CDK6

CDK6

Cyclin-dependent kinase 6 · Q00534 · CDK6 on Sugi Atlas →

96,366 patent compounds predicted against CDK6, 60,966 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL558334 SCHEMBL558334 0.53 14/20
SCHEMBL558335 SCHEMBL558335 0.53 14/20
SCHEMBL303542 SCHEMBL303542 0.80 12/20
SCHEMBL303554 SCHEMBL303554 0.72 9/20
SCHEMBL574660 SCHEMBL574660 0.53 9/20
SCHEMBL559526 SCHEMBL559526 0.47 9/20
SCHEMBL559527 SCHEMBL559527 0.47 9/20
SCHEMBL290253 SCHEMBL290253 0.39 9/20
SCHEMBL525847 SCHEMBL525847 0.73 7/20
SCHEMBL110212 SCHEMBL110212 0.67 7/20
SCHEMBL84453 SCHEMBL84453 0.48 7/20
SCHEMBL344502 SCHEMBL344502 0.60 6/20
SCHEMBL525753 SCHEMBL525753 0.52 6/20
SCHEMBL291478 SCHEMBL291478 0.41 6/20
Riviciclib Riviciclib (SCHEMBL290572) 1.00 5/20
Riviciclib Riviciclib (SCHEMBL291157) 1.00 5/20
Palbociclib Palbociclib (SCHEMBL462630) 1.00 5/20
Riviciclib Riviciclib (SCHEMBL290347) 0.98 5/20
SCHEMBL111812 SCHEMBL111812 0.89 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL175288) 0.87 5/20

Clinical trials — most relevant to CDK6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients PHASE3RECRUITING
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer PHASE3NOT_YET_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study PHASE3RECRUITING
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer PHASE1/PHASE2COMPLETED
Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma PHASE2UNKNOWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
The SONImage Study nanACTIVE_NOT_RECRUITING
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy nanCOMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy nanCOMPLETED
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
BRaziLian outcomE for metAStatic breasT Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK6 binder may also engage these)

ProteinNameSimilarity
Q64261 — 1.000 Q64261 →
Q91727 — 0.995 Q91727 →
A8WIP6 — 0.993 A8WIP6 →
Q12126 — 0.992 Q12126 →
Q38774 — 0.992 Q38774 →
Q38775 — 0.992 Q38775 →
P25859 — 0.992 P25859 →
P35426 — 0.992 P35426 →
Q32KY4 — 0.992 Q32KY4 →
P79432 — 0.992 P79432 →
P30285 — 0.992 P30285 →
Q03147 — 0.991 Q03147 →
Q8L4P8 — 0.991 Q8L4P8 →
P54665 — 0.991 P54665 →
Q2V419 — 0.991 Q2V419 →
Q8SW92 — 0.991 Q8SW92 →
G5EFV5 — 0.990 G5EFV5 →
P54666 — 0.990 P54666 →
P04551 — 0.990 P04551 →
P51952 — 0.990 P51952 →
A8XA58 — 0.989 A8XA58 →
P54119 — 0.989 P54119 →
P54664 — 0.989 P54664 →
P20911 — 0.989 P20911 →
Q00646 — 0.989 Q00646 →
P38973 — 0.989 P38973 →
Q8LG64 — 0.989 Q8LG64 →
Q8LF80 — 0.989 Q8LF80 →
Q03114 — 0.989 Q03114 →
P51166 — 0.988 P51166 →